8-K: PepGen Announces Positive DM1 Data and First Quarter 2025 Financial Results

PepGen reports positive clinical data for its DM1 program and provides a financial update for the first quarter of 2025, highlighting key milestones and upcoming data readouts.

Summary

• PepGen Inc. reported its financial results for the quarter ended March 31, 2025, along with recent corporate highlights.
• The company's cash, cash equivalents, and marketable securities totaled $97.8 million as of March 31, 2025.
• PepGen believes its current cash resources will fund operations for at least the next 12 months.
• Research and Development expenses were $25.4 million for the quarter, compared to $14.7 million in the same period of 2024.
• General and Administrative expenses were $5.9 million, up from $5.1 million in the prior year's quarter.
• Net loss for the quarter was $30.2 million, or $(0.92) per share, compared to a net loss of $18.0 million, or $(0.63) per share, in 2024.
• The company reported positive initial clinical data from the FREEDOM-DM1 trial, with a mean splicing correction of 29.1% observed following a single dose of PGN-EDODM1 at 10 mg/kg.
• Data from the 15 mg/kg cohort of the FREEDOM-DM1 trial is expected in the second half of 2025.
• Data from the 10 mg/kg cohort of the CONNECT1-EDO51 trial is expected in the third quarter of 2025.
• The Phase 2 CONNECT2 trial in DMD patients has been paused until results from the CONNECT1 trial are reviewed.
• Lisa Wyman and Mitchell H. Finer, PhD, joined the company's Board of Directors in March 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical data and financial results. The positive DM1 data and upcoming milestones are encouraging, but the increased net loss and paused clinical trial temper the overall sentiment.

Positives

• Positive initial clinical data from the FREEDOM-DM1 trial showed a mean splicing correction of 29.1% after a single dose of PGN-EDODM1 at 10 mg/kg.
• The company has sufficient cash to fund operations for at least the next 12 months, with $97.8 million in cash, cash equivalents, and marketable securities as of March 31, 2025.
• The addition of Lisa Wyman and Mitchell H. Finer, PhD, to the Board of Directors brings significant industry experience to the company.
• PGN-EDODM1 has been granted both Orphan Drug and Fast Track Designations by the FDA for the treatment of patients with DM1.
• PGN-EDO51 has been granted both Orphan Drug and Rare Pediatric Disease Designations by the FDA for the treatment of patients with DMD amenable to an exon-51 skipping approach.

Negatives

• The company experienced a net loss of $30.2 million for the quarter ended March 31, 2025, which is higher than the $18.0 million loss in the same period of 2024.
• The Phase 2 CONNECT2 trial in DMD patients has been paused until results from the CONNECT1 trial are reviewed.

Risks

• Delays or failure to successfully initiate or complete ongoing and planned development activities for product candidates could impact future results.
• The company's interpretation of clinical and preclinical study results may be incorrect, or the levels of therapeutic activity observed in clinical testing may not meet expectations.
• Product candidates may not be safe and effective or otherwise demonstrate safety and efficacy in clinical trials.
• Adverse outcomes from regulatory interactions, including delays in regulatory review or approval, could impact development programs.
• Unexpected increases in expenses associated with development activities or other events could adversely impact financial resources and cash runway.
• The company's dependence on third parties for manufacturing, research, and preclinical and clinical testing poses a risk.

Future Outlook

PepGen anticipates releasing data from the 15 mg/kg cohort of the FREEDOM-DM1 trial in the second half of 2025, dystrophin production data from the 10 mg/kg cohort of the CONNECT1-EDO51 trial in the third quarter of 2025, and results from the 5 mg/kg cohort of the FREEDOM2-DM1 trial in the first quarter of 2026.

Management Comments

• Our EDO platforms unique ability to efficiently deliver oligonucleotides into the nuclei of cells is the foundation of our differentiated pipeline, with promising clinical data from two programs underscoring what we believe to be the broad potential of our technology, said James McArthur, PhD, President and CEO of PepGen.
• This is a pivotal and catalyst-rich 12 months for PepGen and for our DM1 and DMD clinical programs.

Industry Context

PepGen is operating in the competitive field of oligonucleotide therapies, targeting severe neuromuscular and neurological diseases. The company's focus on enhanced delivery of oligonucleotides aims to improve efficacy and overcome limitations of existing treatments for diseases like DM1 and DMD.

Comparison to Industry Standards

• The reported 29.1% mean splicing correction in DM1 patients following a single dose of PGN-EDODM1 is a promising result and could position PepGen competitively against other companies developing DM1 therapies, such as Avidity Biosciences and Biogen.
• Avidity Biosciences' AOC 1001 has shown improvements in splicing and myotonia in DM1 patients, while Biogen is developing antisense oligonucleotides for DM1.
• PepGen's approach of using Enhanced Delivery Oligonucleotides (EDOs) aims to improve the uptake and activity of conjugated oligonucleotide therapeutics, potentially offering advantages over traditional oligonucleotide delivery methods.
• For DMD, companies like Sarepta Therapeutics and NS Pharma have approved exon-skipping therapies, but PepGen's PGN-EDO51 targets exon 51, which is relevant for approximately 13% of DMD patients, and the company aims to improve dystrophin production through its EDO technology.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the promising clinical data and upcoming milestones, but negatively to the increased net loss.
• Patients with DM1 and DMD may benefit from the development of PGN-EDODM1 and PGN-EDO51, respectively.
• Employees are likely to be impacted by the company's prioritization of clinical milestones and measures to extend the cash runway.

Next Steps

• Report safety, 28-day splicing and functional benefit data from the 15 mg/kg cohort of the FREEDOM trial during the second half of 2025.
• Report additional safety as well as dystrophin production data from the 10 mg/kg cohort of the CONNECT1 trial in DMD patients in the third quarter of 2025.
• Report results from the 5 mg/kg cohort of the FREEDOM2 trial in the first quarter of 2026.

Key Dates

Keywords

PepGen, PGN-EDODM1, PGN-EDO51, Myotonic Dystrophy Type 1, Duchenne Muscular Dystrophy, DM1, DMD, Oligonucleotide therapies, Financial Results, Clinical Trial, Splicing Correction, Dystrophin Production